Myriad Genetics, Inc. disclosed its first-quarter results for 2026 on May 5, during the earnings call. Key metrics showed earnings per share (EPS) at -$0.09, falling short of expectations by $0.02. Revenue reached $200.40 million, marking a 2.30% increase year-over-year but missing forecasts by $2.04 million.
Financial Highlights
Analysts anticipated stronger performance, yet the figures reflect modest growth amid ongoing market pressures. The revenue uptick signals steady demand for the company’s genetic testing services, though profitability challenges persist.
Key Metrics Breakdown
- EPS: -$0.09 (missed consensus by $0.02)
- Revenue: $200.40M (+2.30% YoY, missed by $2.04M)
Investors await further details from management on strategic initiatives to boost future quarters. Myriad Genetics continues to focus on expanding its portfolio in hereditary cancer testing and precision medicine.
